Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on erectile activity in males suffering from erectile dysfunction as well as examining the safety and toleration of the drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• Males aged 18-65 years who has given written informed consent to participate in the study and who suffers moderate to severe erectile dysfunction who has a current or recent successful response to treatment with phosphodiesterase type 5 inhibitors

Exclusion Criteria:

• Males with a history of significant cardiac disease; unstable angina or recent myocardial infarction.

• Males suffering from treated or untreated hypo- or hypertension

• Males currently receiving vasoactive medication

• Males taking medications contraindicated, or cautioned with sildenafil or MC4 agonists